Shenzhen YHLO Biotech Co., Ltd. Stock: price and insider trades · China
亚辉龙
1 insider bought €960k of shares over the last 90 days, the latest by 胡鹍辉, filed 16 Oct 2026.
Shenzhen YHLO Biotech Co., Ltd.: what insiders have been doing
Shenzhen YHLO Biotech Co., Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). Over the twelve months to 5 November 2026, 10 filings were filed, from 1 insider.
Purchases and sales both appear in the filings: 6 purchases (1 insider, €1.3M) and 4 sales (1 insider, €2.1M). Netting one side against the other leaves €825k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 board member and 1 chief executive. At €570k, the sale published on 18 November 2025 by 胡鹍辉 is the largest of the period.
With 10 filings in twelve months, the company is more active than the median of 2 filings across the 514 companies we follow on the same exchange. Looking back to 2022, when coverage begins, insiders filed 8 purchases and 10 sales.
The most recent open-market purchase was published on 16 October 2026, 23 days ago. Publication is fast: at least half of the trades appear on SSE / SZSE (CSRC) on the same day. This delay matters because a trade only becomes useful information once it is public.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- +8.2%Entry CN¥10.12 · Close 03 Nov 2026 CN¥10.95
- -36.5%Entry CN¥23.14 · Close at T+365 CN¥14.70
- -34.3%Entry CN¥29.02 · Close at T+365 CN¥19.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Shenzhen YHLO Biotech Co., Ltd. Strong Buy (bullish), based on 3 analysts. Average price target: CN¥16.01.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 229,370 shares@ CN¥77.18229.3% of flowA股XSHGSSE:273000001721654340Canonical exit: 14 Jan 2027 (T+90)
- 200,000 shares@ CN¥76.14528.9% of flowA股XSHGSSE:273000001704615650Canonical exit: 12 Jan 2027 (T+90)
- 30,000 shares@ CN¥73.05731.1% of flowA股XSHGSSE:273000001545268800Canonical exit: 15 Dec 2026 (T+90)
- 260,000 shares@ CN¥79.132610.0% of flowA股XSHGSSE:273000001466506180Canonical exit: 7 Dec 2026 (T+90)
- 100,000 shares@ CN¥70.53664.2% of flowA股XSHGSSE:273000000866405060Canonical exit: 19 Oct 2026 (T+90)
- 167,000 shares@ CN¥70.62877.0% of flowA股XSHGSSE:273000000738609200Canonical exit: 15 Sept 2026 (T+90)
- 300,000 shares19.4% of flowA股XSHGSSE:173000009856792960
- 230,000 shares15.3% of flowA股XSHGSSE:173000009822885500
- 300,000 shares20.2% of flowA股XSHGSSE:173000009814501950
- 300,000 shares20.4% of flowA股XSHGSSE:173000009800874200
- 100,000 shares89.0% of flowA股XSHGSSE:173000009659360480
- 10,000 shares8.8% of flowA股XSHGSSE:173000009655626940
- 2,561 shares2.2% of flowA股XSHGSSE:173000009652162300
- 130,000 shares52.0% of flowA股XSHGSSE:173000008719093100
- 120,000 shares48.0% of flowA股XSHGSSE:173000008705772320
- 33,220 shares100.0% of flowA股XSHGSSE:173000007677925000Canonical exit: 20 Aug 2024 (T+90)
- 532,000 shares100.0% of flowA股XSHGSSE:173000005539459000
- 300 shares100.0% of flowA股XSHGSSE:173000005661774300Canonical exit: 12 Jul 2022 (T+90)
18 of 18 declarations
About Shenzhen YHLO Biotech Co., Ltd.
亚辉龙 is a company in the health and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and production of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
